73718-79-3

Upstream product

• 62451-84-7 (3-trifluoromethyl-phenyl)-acetic acid methyl ester 
• 756-79-6 dimethyl methane phosphonate 
• 346672-98-8 N-methoxy-N-methyl-2-[3-(trifluoromethyl)phenyl]acetamide 
• 351-35-9 3-(trifluoromethyl)phenylacetic acid 

Downstream Products

• 884490-86-2 5-(3-{2-oxo-5R-[3-oxo-4-(3-trifluoromethyl-phenyl)-but-1-enyl]-pyrrolidin-1-yl}-propyl)-thiophene-2-carboxylic acid methyl ester 
• 1365392-10-4 C₂₂H₂₈F₃NO₄S 
• 494222-26-3 4-[(2-{(2R)-2-[(1E,3S)-3-hydroxy-4-(3-trifluoromethylphenyl)but-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)sulfanyl]butanoic acid 
• 533893-74-2 ethyl 7-[(2R)-2-{(1E,3S)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-buten-1-yl}-5-oxo-1-pyrrolidinyl]heptanoate 
• 492471-66-6 (4-{(R)-2-Oxo-5-[(E)-3-oxo-4-(3-trifluoromethyl-phenyl)-but-1-enyl]-pyrrolidin-1-yl}-butoxy)-acetic acid ethyl ester 
• 533893-84-4 7-{(R)-2-Oxo-5-[(E)-3-oxo-4-(3-trifluoromethyl-phenyl)-but-1-enyl]-pyrrolidin-1-yl}-heptanoic acid ethyl ester 

Relevant academic research and scientific papers

Discovery of orally available 8-aza-5-thiaProstaglandin E1 analogs as highly selective EP4 agonists

Analogs 8-aza-16-aryl prostaglandin E1 (PGE1) and 8-aza-5-thia-16-arylPGE1 were synthesized and evaluated with respect to their subtype receptor affinity and EP4 agonist activity for the purposes of identifying sub-type- selective EP

Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization.

A series of 7-[(5R)-substituted 2-oxo-1-pyrrolidinyl]-heptanoic acids were prepared, their isomeric purity determined, and pharmacologically evaluated. Lactams with affinity for the EP(4) receptor displayed agonist behavior. The lower side-chain of the la

EP4 receptor selective agonists in the treatment of osteoporosis

This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, wherein R2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.

EP4 receptor selective agonists in the treatment of osteoporosis

This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. This invention is especially directed to those methods wherein the EP4 receptor selective agonist is a compound of Formula I: wherein the variables are as defined in the specification.